Merck and Moderna announced Wednesday the initiation of a pivotal Phase III high-risk melanoma trial combining the companies’ mRNA-based personalized cancer vaccine with Merck’s blockbuster Keytruda checkpoint inhibitor.
Clinical Trials
mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma
The combination of mRNA-4157 (V940) and pembrolizumab (Keytruda) will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial (NCT05933577).
Atezolizumab, Vemurafenib, and Cobimetinib in Patients With BRAF V600–Mutated Melanoma and CNS Metastases
A revised report of findings from the phase II TRICOTEL study of atezolizumab, vemurafenib, and cobimetinib in patients with melanoma and central nervous system (CNS) metastases was published in The Lancet Oncology by Reinhard Dummer, MD, and colleagues. The first version of trial findings, published online in August 2022, was retracted.
Merck and Moderna announce Phase III V940 trial for melanoma patients
Merck (MSD) and Moderna are initiating a Phase III trial evaluating V940, an investigational individualised neoantigen therapy (INT), in combination with Keytruda, to treat patients with resected high-risk (Stage IIB-IV) melanoma.